Breaking News Instant updates and real-time market news.

CELG

Celgene

$105.46

-0.03 (-0.03%)

, DOVA

Dova Pharmaceuticals

$30.05

0.01 (0.03%)

04:55
01/11/18
01/11
04:55
01/11/18
04:55

JPMorgan to hold a conference

36th Annual Healthcare Conference is being held in San Francisco on January 8-11.

CELG

Celgene

$105.46

-0.03 (-0.03%)

DOVA

Dova Pharmaceuticals

$30.05

0.01 (0.03%)

AGN

Allergan

$173.99

-1.66 (-0.95%)

BSX

Boston Scientific

$27.52

-0.44 (-1.57%)

EXAS

Exact Sciences

$53.96

1.49 (2.84%)

FPRX

Five Prime

$22.13

0.17 (0.77%)

RGEN

Repligen

$36.47

-0.02 (-0.05%)

ILMN

Illumina

$242.59

-0.21 (-0.09%)

ABT

Abbott

$58.55

-0.09 (-0.15%)

BIVV

Bioverativ

$58.75

-0.28 (-0.47%)

WBA

Walgreens Boots Alliance

$74.08

0.66 (0.90%)

GBT

Global Blood Therapeutics

$55.45

8.3 (17.60%)

IDXX

IDEXX

$166.14

0.41 (0.25%)

AMED

Amedisys

$51.10

0.48 (0.95%)

CI

Cigna

$207.09

-0.78 (-0.38%)

MYOK

MyoKardia

$48.45

0.9 (1.89%)

PODD

Insulet

$75.83

0.75 (1.00%)

AXON

Axovant Sciences

$2.43

0.05 (2.10%)

IPXL

Impax

$17.35

0.05 (0.29%)

FMI

Foundation Medicine

$69.65

1.5 (2.20%)

THC

Tenet

$14.77

-0.34 (-2.25%)

VAR

Varian Medical

$111.68

-1.25 (-1.11%)

  • 11

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 08

    Feb

  • 16

    Feb

  • 26

    Feb

  • 25

    Mar

  • 25

    Apr

  • 21

    May

CELG Celgene
$105.46

-0.03 (-0.03%)

01/09/18
JEFF
01/09/18
NO CHANGE
Target $125
JEFF
Buy
Celgene likely 'too cheap and oversold,' says Jefferies
Jefferies analyst Michael Yee says that at 12 times earnings estimates, shares of Celgene are "probably too cheap and oversold." After meeting with management, Yee believes the company will do more deals following yesterday's acquisition of Impact. Further, he sees a potential share rebound on more pipeline readouts in 2018-2019. The analyst keeps a Buy rating on Celgene with a $125 price target.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $147
BMOC
Outperform
Celgene 2018 outlook deliberately conservative, says BMO Capital
BMO Capital analyst M. Ian Somaiya says Celgene's 2018 guidance is "deliberately conservative", reflecting the management's decision to reduce the risk to near-term estimates amid investor focus on the company pipeline. Somaiya notes that investor focus is shifting to business development and the potential for more deals in the near-term as well as the data from the company's 12 phase III trials this year. The analyst keeps his Outperform rating and $147 price target on Celgene.
01/08/18
ADAM
01/08/18
NO CHANGE
Target $140
ADAM
Buy
Celgene acquisition has 'interesting' upside potential, says Canaccord
After Celgene announced a deal to acquire Impact Biosciences for up to $7B, including an upfront payment of $1.1B, Canaccord analyst John Newman said the latter's JAK2 asset for myelofibrosis, fedratinib, showed an "interesting" 55% response rate in patients resistant or intolerant to Jakafi, which provides an immediately approvable FDA indication. This "carefully structured transaction" provides Celgene with substantial upside, assuming FDA approval, said Newman, who keeps a Buy rating and $140 price target on Celgene shares.
01/08/18
PIPR
01/08/18
NO CHANGE
Target $100
PIPR
Neutral
Celgene guidance 'a bit light' on sales, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views Celgene's preliminary Q4 results as "solid' but says the company's initial 2018 outlook is "a bit light" on revenue. The better than expected earnings outlook looks to be driven by expense management and lower than modeled share count, Raymond tell investors in a research note. He keeps a Neutral rating on Celgene with a $100 price target.
DOVA Dova Pharmaceuticals
$30.05

0.01 (0.03%)

09/26/17
LEER
09/26/17
UPGRADE
LEER
Outperform
Dova Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
11/28/17
JEFF
11/28/17
NO CHANGE
Target $33
JEFF
Buy
Dova Pharmaceuticals price target raised to $33 from $30 at Jefferies
Jefferies analyst Eun Yang raised her price target for Dova Pharmaceuticals to $33 after avatrombopag received FDA priority review with an action date of May 21, 2018. The analyst sees a higher probability for regulatory success of 95% and potential approval three months earlier than previously thought. She keeps a Buy rating on Dova.
09/26/17
09/26/17
UPGRADE
Target $32

Outperform
Dova Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded Dova Pharmaceuticals to Outperform from Market Perform after Shionogi announced results from its phase III trial investigating thrombopoietin receptor agonist lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure. The analyst notes that lusutrombopag is from the same class of drugs as Dova's avatrombopag, but is less effective ex-Japan, and believes Dova's avatrombopag has advantage. Porges also raised his price target on Dova's shares to $32 from $24.
08/31/17
RAJA
08/31/17
NO CHANGE
RAJA
Market Perform
Investors wrong to think Fosun will acquire Impax, says Raymond James
Raymond James analyst Elliot Wilbur says shares of Impax Laboratories (IPXL) are up 20% after Shanghai Fosun Pharmaceutical disclosed this morning a 5.19% stake in the company. Investors interpreting the investment as strategic, setting up an eventual takeover of Impax, is inaccurate, Wilbur tells investors in a research note. The analyst points out that Shanghai Fosun has a New York-based investment arm with positions in companies including Valeant Pharmaceuticals (VRX), Dova Pharmaceuticals (DOVA) and Nature's Sunshine Products (NATR). The stake is just a passive investment made because the investment arm of Shanghai Fosun believes in the Impax turnaround story "and nothing more," Wilbur contends. He keeps a Market Perform rating on Impax. The stock in afternoon trading is up 20%, or $3.62, to $21.58.
AGN Allergan
$173.99

-1.66 (-0.95%)

01/10/18
UBSW
01/10/18
NO CHANGE
Target $250
UBSW
Buy
Allergan set up well for 2018, says UBS
UBS analyst Marc Goodman noted Allergan's 2018 guidance was a little light on the top-line, but management is pledging to be aggressive with cost cutting and expects tax reform to have a largely neutral long-term impact. The analyst said he likes the setup for 2018 as the focus will turn to its pipeline and key events over the next six months. Goodman reiterated his Buy rating and $250 price target on Allergan shares.
01/09/18
MSCO
01/09/18
NO CHANGE
Target $200
MSCO
Overweight
Morgan Stanley sees Allergan expectations near bottom, stays Overweight
Morgan Stanley analyst David Risinger cut his 2018 revenue forecast for Allergan by 4% and his EPS view by 8% after the company gave initial 2018 guidance that factors in generic and tax headwinds. While the negative impact of generics is worse than expected, Risinger contends that its 2018 non-GAAP EPS view likely marks a bottom in the company's long-term earnings power. The analyst, who sees significant upside potential for Allergan in 2018 if its readouts for CGRP in migraine and abicipar in AMD are encouraging, maintains his Overweight rating and $200 price target on the shares.
01/09/18
DBAB
01/09/18
NO CHANGE
Target $215
DBAB
Buy
Allergan price target lowered to $215 from $235 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert lowered his price target for Allergan to $215 citing more conservative sales estimates for several products, lower gross margin, and a higher tax rate. The analyst, however, keeps a Buy rating on the shares. He still views Allergan as a "reasonably valued stock" with an attractive growth profile and diverse franchises.
01/05/18
WELS
01/05/18
NO CHANGE
Target $245
WELS
Outperform
Allergan has built 'great barrier' around Botox, says Wells Fargo
Wells Fargo analyst David Maris conducted a survey of 25 plastic surgeons and dermatologists to gain insight on the changing neurotoxin landscape. The survey shows Allergan's (AGN) patient and physician loyalty programs and bundling discounts create a "great barrier" around Botox, Maris tells investors in a research note. It is unclear how significant a potential competitor Revance's (RVNC) RT002 could be to Allergan's largest product, the analyst adds. He believes that even with new innovative treatment options, Botox is expected to maintain its dominance in the neurotoxin market. Further, the analyst says that while RT002 showed statistically significant results at week 24 versus placebo, the endpoint doesn't seem not match the FDA's published guidance. Maris wonders if the data will be enough to get a six-month duration claim on the RT002 label, or if Revance is just hoping for an approval and then will point to the duration data. He keeps an Outperform rating on Allergan with a $245 price target.
BSX Boston Scientific
$27.52

-0.44 (-1.57%)

01/09/18
LEER
01/09/18
NO CHANGE
LEER
Outperform
Boston Scientific should outperform on 'strong beat,' says Leerink
Leerink analyst Danielle Antalffy notes that Boston Scientific preannounced better than expected Q4 results. The analyst sees this quarterly performance as particularly encouraging, given the fact that Boston Scientific delivered outperformance across all business segments despite facing a tough comp. Antalffy expects the stock to outperform on this strong beat, and continues to believe Boston Scientific represents "one of the most attractive" top-line growth stories in large-cap MedTech. She reiterates an Outperform rating on the shares.
01/05/18
RBCM
01/05/18
UPGRADE
Target $31
RBCM
Top Pick
Boston Scientific upgraded to Top Pick at RBC Capital
As reported earlier, RBC Capital analyst Glenn Novarro upgraded Boston Scientific to Top Pick from Outperform, keeping his $31 price target. Novarro says the Q4 earnings expected out on February 1st will be a positive catalyst in addressing concerns around 2018 outlook in late November when the company announced another delay in its LOTUS Edge system.
01/05/18
RBCM
01/05/18
UPGRADE
RBCM
Top Pick
Boston Scientific upgraded to Top Pick from Outperform at RBC Capital
01/03/18
EVER
01/03/18
INITIATION
Target $27
EVER
In Line
Boston Scientific initiated with an In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar started Boston Scientific with an In Line rating and $27 price target, stating that a lack of Lotus upside sets it up as a decelerating topline story.
EXAS Exact Sciences
$53.96

1.49 (2.84%)

01/02/18
WBLR
01/02/18
NO CHANGE
WBLR
Outperform
Exact Sciences went out of network with Anthem Blue Cross, says William Blair
William Blair analyst Brian Weinstein notes Anthem Blue Cross, which represents Indiana, Kentucky, Missouri, Ohio, and Wisconsin, published a Network eUpdate late last week that included an in-network laboratory update for Exact Sciences. The update, which does not affect the positive coverage decision from Anthem Blue Cross, is the result of a request from Exact Sciences to move from an in-network, contracted lab to an out-of-network provider with this payer, Weinstein tells investors in a research note. The switch became effective January 1, 2018. The analyst views the decision by the company with Anthem Blue Cross as a "specific situation" and believes it does not alter the uptake trajectory of Exact's Cologuard. Further, the switch should result in improving revenue per test at the company, Weinstein adds. He keeps an Outperform rating on Exact Sciences.
01/02/18
BOFA
01/02/18
NO CHANGE
BOFA
BofA/Merrill's Top 10 US Ideas for Q1 2018
BofA/Merrill named its Top 10 Ideas for Q1 2018. They are Buy rated AMD (AMD), Disney (DIS), Exact Sciences (EXAS), Exelon (EXC), lululemon (LULU), PayPal (PYPL), United Rentals (URI), and Walmart (WMT), and Underperform rated L Brands (LB) and TripAdvisor (TRIP).
01/03/18
ADAM
01/03/18
NO CHANGE
ADAM
Canaccord names Illumina among top 2018 picks in Diagnostics and Tools industry
Canaccord analyst Mark Massaro rolled out his top 2018 picks in the Diagnostics and Tools segment after noting his 2017 picks returned 38% overall. He said he prefers larger companies in 2018 and said Illumina (ILMN) is a must own here due to its continued market dominance. The analyst raised his price target to $255 from $235 on Illumina shares. The analyst also recommends Exact Sciences (EXAS) as he expects its strong growth to continue. Massaro reiterated his $60 price target on Exact Sciences shares. He also likes Hologic (HOLX) and expects 2018 to be a bounce back year, raising his price target to $50 from $44. The analyst also likes Lab Corp. (LH) and believes it is likely to see an earnings acceleration and multiple expansion. He raised his price target to $190 from $175 on Lab Corp. shares. Finally, Massaro likes IDEXX (IDXX) for its new product launches and underlying global trends, keeping a $180 price target on the shares.
01/08/18
BNCH
01/08/18
NO CHANGE
Target $65
BNCH
Buy
Exact Sciences price target raised to $65 from $60 at Benchmark
After Exact Sciences preannounced Q4 preliminary results, Benchmark analyst Raymond Myers said the results looked strong overall even though Cologuard's growth in the quarter in terms of number of tests was slightly slower than he had forecast. He calculated that revenue per test expanded $46 quarter-over-quarter to $497. Myers, who raised his price target on Exact Sciences shares to $65, keeps a Buy rating on the stock.
FPRX Five Prime
$22.13

0.17 (0.77%)

11/13/17
NOMU
11/13/17
NO CHANGE
Target $94
NOMU
Buy
Five Prime recent selloff looks unfounded, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes the cabira+nivo data has been taken out of context and that the recent selloff in shares of Five Prime Therapeutics looks unfounded. The data highlight "remarkable durable responses in patients not expected to respond," Marai tells investors in a research note. He points out that the IDO inhibitor epacadostat routinely only results in 10% benefit in overall response rate. Marai keeps a Buy rating on Five Prime with a $94 price target.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/07/17
SBSH
11/07/17
NO CHANGE
Target $65
SBSH
Buy
Citi says data puts safety of Five Prime's cabiralizumab in question
The key point of today's abstract was 43% G3-5 toxicity related to Five Prime Therapeutics' cabiralizumab, which puts the safety of the drug in question, Citi analyst Robyn Karnauskas tells investors in a research note. The analyst, who notes the data do show some durable activity, does not know at what dose the safety issues occurred. It remains unclear at this point if the activity being seen is due to checkpoint or cabiralizumab's contribution, Karnauskas writes. She models a 35% probability to the cabiralizumab program, which contributes $34 to her price target of $65. The analyst has a Buy rating on Five Prime. The stock is down 34% to $28.67.
11/07/17
JEFF
11/07/17
NO CHANGE
Target $52
JEFF
Buy
Five Prime data not as strong as expected, says Jefferies
Jefferies analyst Eun Yang says the 10% overall response rate with Five Prime Therapeutics' cabiralizumab plus Opdivo in second-line pancreatic cancer is lower than expected and the six-month disease control rate of 13%. The data are "not as strong as we like to see," but compares reasonably to chemo combo in second-line pancreatic cancer, Yang tells investors in a research note. The analyst has a Buy rating on Five Prime Therapeutics with a $52 price target. The stock in midday trading is down 34% to $28.69.
RGEN Repligen
$36.47

-0.02 (-0.05%)

12/05/17
JPMS
12/05/17
INITIATION
Target $42
JPMS
Overweight
Repligen initiated with an Overweight at JPMorgan
JPMorgan analyst Tycho Peterson started Repligen with an Overweight rating and $42 price target. The analyst views the company as the "best pure-play bioprocessing supplier."
12/05/17
12/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Repligen (RGEN) initiated with an Overweight at JPMorgan. 2. Delphi Technologies (DLPH) was initiated with an Overweight at Morgan Stanley and a Buy at Goldman Sachs. 3. Aptiv (APTV) initiated with an Underweight at Morgan Stanley. 4. Michael Kors (KORS) reinstated with a Buy at Goldman Sachs. 5. Bandwidth (BAND) was initiated with an Outperform at Baird and JMP Securities, an Overweight at KeyBanc and Morgan Stanley, as well as a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/08/17
SBSH
12/08/17
INITIATION
Target $45
SBSH
Buy
Repligen initiated with a Buy at Citi
Citi analyst Daniel Arias started Repligen with a Buy rating and $45 price target. Repligen is well positioned as a pure-play within one of the most attractive portions of the life sciences market, Arias tells investors in a research note. The analyst believes the recent pullback provides a good buying opportunity.
11/13/17
KING
11/13/17
INITIATION
Target $41
KING
Buy
Repligen initiated with a Buy at CL King
CL King initiated Repligen with a Buy and $41 price target telling investors its premium valuation is justified given potential strong double-digit growth and operating margin expansion.
ILMN Illumina
$242.59

-0.21 (-0.09%)

01/09/18
WELS
01/09/18
NO CHANGE
Target $260
WELS
Outperform
Illumina price target raised to $260 from $250 at Wells Fargo
Wells Fargo analyst Tim Evans raised his price target for Illumina (ILMN) to $260 from $250 after the company delivered a host of positive updates, namely a positive pre-announce of Q4 revenue, above-consensus revenue and EPS guidance for 2018, the official launch of Firefly, the launch of faster library prep consumables, and a collaboration with Thermo Fisher (TMO) to run AmpliSeq on Illumina instruments. The analyst reiterates an Outperform rating on Illumina's shares.
01/05/18
WBLR
01/05/18
DOWNGRADE
WBLR
Market Perform
Illumina downgraded to Market Perform from Outperform at William Blair
William Blair analyst Amanda Murphy downgraded Illumina to Market Perform citing valuation and where the company is in the new product cycle adoption curve. Instrumentation comparisons become much more difficult after the second quarter of of 2018, Murphy tells investors in a research note. The analyst adds that estimates for 2018 revenue growth have crept up and are now at 14%.
01/05/18
BTIG
01/05/18
INITIATION
BTIG
Neutral
Illumina initiated with a Neutral at BTIG
BTIG analyst Sung Ji Nam started Illumina with a Neutral rating citing uncertainty over the magnitude of HiSeq/HiSeq X customer conversion in the near-term.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $274
PIPR
Overweight
Illumina price target raised to $274 from $228 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Illumina to $274 citing his positive channel checks in Q4. His checks found 57 NovaSeq installs during Q4, compared to his 95 modeled estimate. The analyst notes that Illumina placed 90 NovaSeqs during Q3 after his checks found 50. Quirk sees see potential upside driven by the array business and keeps an Overweight rating on Illumina shares.
ABT Abbott
$58.55

-0.09 (-0.15%)

01/04/18
COWN
01/04/18
NO CHANGE
Target $70
COWN
Outperform
Dexcom selling off too much on Abbott news, says Cowen
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
01/05/18
WBLR
01/05/18
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom remaining 'product-of-choice' in glucose monitoring
William Blair analyst Margaret Kaczor believes Dexcom (DXCM) will remain the "product-of-choice" in glucose monitoring after Abbott (ABT) received Medicare approval for its Freestyle Libre Flash. While the approval comes six to nine months earlier than anticipated, Abbott's broader presence will likely expand patient awareness, Kaczor tells investors in a research note. She believes Dexcom is well positioned given its alerts and alarms in this "more vulnerable patient population." The analyst keeps an Outperform rating on the shares following yesterday's selloff.
01/05/18
LEER
01/05/18
NO CHANGE
Target $75
LEER
Outperform
Dexcom pricing risk less bad than feared, says Leerink
Leerink analyst Danielle Antalffy says her conversation with a specialist reinforced her view that Dexcom (DXCM) will continue to warrant at least some price premium to Abbott's (ABT) Libre given its alert and alarm capabilities and what is presumably better outcomes for patients. The analyst continues to recommend buying Dexcom on yesterday's, particularly for investors with at least a six month time horizon. She reiterates an Outperform rating on the shares with a $75 price target. Antalffy sees the company's pricing risk as less bad than feared following yesterday's news of Abbott securing Medicaid approval sooner than expected for its Freestyle Libre.
BIVV Bioverativ
$58.75

-0.28 (-0.47%)

11/20/17
PIPR
11/20/17
NO CHANGE
Target $71
PIPR
Overweight
Piper a buyer of Bioverativ on Roche study selloff
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Bioverativ (BIVV) after Roche (RHHBY) announced that its Haven 3 Phase III study met its primary endpoint. The analyst is waiting for the full data, expected in May, regarding absolute annualized bleed rates and consistency of effect. He remains confident in his forward estimates for Bioverativ's Eloctate and keeps an Overweight rating on the shares with a $71 price target. Absent full data detailing absolute annualized bleed rates for Roche's Hemlibra, it's difficult to draw too many conclusions on the relative efficacy compared to Eloctate in the non-inhibitor population, Raymond tells investors in a research note.
11/20/17
DBAB
11/20/17
NO CHANGE
Target $53
DBAB
Hold
Deutsche cuts Bioverativ target to $53 after positive Roche data
Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.
11/16/17
RBCM
11/16/17
NO CHANGE
RBCM
Top Pick
Roche approval neutral to slightly negative for Shire, says RBC Capital
RBC Capital analyst Douglas Miehm views the FDA approval for Roche's (RHHBY) Hemlibra as neutral to slight negative for Shire (SHPG). The approval comes three months early while the labeling for the hemophilia A drug contains a black box warning that severe blood clots may occur when Hemlibra is used with Feiba, Miehm tells investors in a research note. He believes investors will be "somewhat surprised" by the early timing of the approval but not surprised by the black box warning. He notes his estimates for Shire already reflect a 73% decline in inhibitor revenue from 2017 through 2025. Miehm keeps an Outperform rating on Shire. The stock in afternoon trading is up 5% to $146.66. Bioverativ (BIVV), another company with a hemophilia A treatment, is up 2% to $56.45.
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
WBA Walgreens Boots Alliance
$74.08

0.66 (0.90%)

01/03/18
LOOP
01/03/18
NO CHANGE
Target $90
LOOP
Buy
High flu incidence to boost Walgreens Boots Alliance earnings, says Loop Capital
Loop Capital analyst Andrew Wolf says the "much higher" than normal rate of flu incidence this season bodes positively for Walgreens Boots Alliance, which is set to report its Q1 earnings tomorrow. Wolf keeps his Buy rating and $90 price target on the company, but raises is Q1 and FY18 EPS projections by 5c per share.
01/09/18
FBCO
01/09/18
NO CHANGE
Target $97
FBCO
Outperform
Walgreens Boots Alliance removed from U.S. Focus List at Credit Suisse
Credit Suisse's Investment Policy Committee has removed Walgreens Boots Alliance from its U.S. Focus List, as the stock is no longer considered one of its top investment ideas. The firm has an Outperform rating and $97 price target on the shares.
01/02/18
LEER
01/02/18
NO CHANGE
Target $105
LEER
Outperform
AmerisourceBergen price target raised to $105 from $90 at Leerink
Leerink analyst David Larsen raised his price target for AmerisourceBergen (ABC) to $105 from $90, citing the H.D. Smith transaction and a more positive outlook for 2018 and 2019. The analyst notes that the company has completed its major renewals, generic deflation is stabilizing, and it will benefit from Prime, Rite Aid (RAD) and Walgreens Boots Alliance (WBA) volumes in 2018. He reiterates an Outperform rating on the shares.
01/04/18
EVER
01/04/18
INITIATION
Target $80
EVER
Outperform
Walgreens Boots Alliance initiated with an Outperform at Evercore ISI
Evercore ISI started Walgreens Boots Alliance with an Outperform rating and $80 price target.
GBT Global Blood Therapeutics
$55.45

8.3 (17.60%)

12/14/17
NEED
12/14/17
NO CHANGE
Target $70
NEED
Buy
Global Blood Therapeutics price target raised to $70 from $51 at Needham
Needham analyst Danielle Brill raised her price target on Global Blood Therapeutics to $70, saying the company is her top pick going into 2018. Brill notes her "conviction for a positive outcome from Part A of the Phase 3 HOPE trial" in the first half of next year after the latest data updates at ASH, as the safety and efficacy profile of voxeletor remain encouraging. The analyst keeps her Buy rating on Global Blood Therapeutics, adding that the recent pullback in shares creates an attractive opportunity for investors.
12/12/17
EAMC
12/12/17
NO CHANGE
Target $58
EAMC
Global Blood Therapeutics weakness a buying opportunity, says Empire
Empire said Global Blood Therapeutics' weakness seems to be related to both enthusiasm for ASH presentations on potential curative SCD gene therapies and a misunderstanding about two deaths in a voxelotor compassionate use program that were deemed unrelated to voxelotor therapy. The firm, which does not consider potential gene therapies to cure SCD as a major threat to voxelotor, keeps a $58 price target on the stock and views the post-ASH weakness as a buying opportunity.
12/12/17
OPCO
12/12/17
NO CHANGE
Target $79
OPCO
Outperform
Global Blood Therapeutics price target raised to $79 from $53 at Oppenheimer
Oppenheimer analyst Mark Breidenbach raised his price target for Global Blood Therapeutics to $79 from $53 given new clinical data and improved clarity on the performance of the Patient Reported Outcome instrument. The analyst reiterates an Outperform rating on the shares.
12/11/17
MSCO
12/11/17
NO CHANGE
Target $55
MSCO
Overweight
Global Blood Therapeutics ASH update 'solid,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison called the interim data presented by Global Blood Therapeutics for its Phase 2a trial of GBT440 in adolescents "solid" and encouraging in terms of the potential response in Phase 3. He maintains an Overweight rating and $55 price target on Global Blood Therapeutics shares, which are down 6% to $43 in pre-market trading.
IDXX IDEXX
$166.14

0.41 (0.25%)

08/23/17
08/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Rockwell Collins (COL) upgraded to Buy from Hold at Vertical Research by analyst Robert Stoddard, as he believes there remains the possibility of the company being acquired. As detailed in colleague Jeff Sprague's related report United Technologies (UTX), the two analysts cannot rule out United Technologies making a bid for Rockwell Collins. They believe it could be more exotically structured as a Reverse Morris Trust, which would make a transaction more financially appealing to United Technologies shareholders, while preserving its credit rating, and providing Rockwell Collins shareholder with a decent premium. 2. JD.com (JD) upgraded to Buy from Hold at MKM Partners by analyst Rob Sanderson based on valuation and his belief that Chinese e-commerce is powerful enough to support "a strong number two," while the company's "position" is "sustainably differentiated." 3. IDEXX (IDXX) upgraded to Buy from Neutral at BofA/Merrill by analyst Derik De Bruin, who said new data supports 10% long-term organic revenue and 15%-20% earnings CAGRs through 2022 driven by higher diagnostic utilization by the installed base, new product ramps, and further innovation. The analyst said the pullback since the solid Q2 report provides a buying opportunity for this "top dog." 4. Intuit (INTU) upgraded to Equal-Weight from Underweight at First Analysis by analyst James Macdonald, who raised his price target to $128 from $102 following the "strong" quarter and better than expected 2018 guidance driven by Small Business growth. 5. G-III Apparel (GIII) upgraded to Overweight from Neutral at Piper Jaffray by analyst Erinn Murphy to reflect the recent pullback in shares and maintained a $27 price target. The analyst expects wholesale trends to "fuel upside" and believes the new DKNY product is checking well at retail. To see The Fly's full Street Research coverage, click here.
07/28/17
KING
07/28/17
UPGRADE
KING
Buy
IDEXX upgraded to Buy from Neutral at CL King
08/23/17
BOFA
08/23/17
UPGRADE
Target $175
BOFA
Buy
IDEXX upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded IDEXX to Buy from Neutral and maintained a $175 price target following last week's Analyst Day. The analyst said new data supports 10% long-term organic revenue and 15%-20% earnings CAGRs through 2022 driven by higher diagnostic utilization by the installed base, new product ramps, and further innovation. The analyst said the pullback since the solid Q2 report provides a buying opportunity for this "top dog."
AMED Amedisys
$51.10

0.48 (0.95%)

11/09/17
BNCH
11/09/17
DOWNGRADE
BNCH
Hold
Amedisys downgraded to Hold from Buy at Benchmark
Benchmark analyst Bill Sutherland downgraded Amedisys to Hold from Buy as he believes the company's improving fundamentals are now reflected in the stock after its 25% advance since last week's CMS decision to not pursue an onerous rate proposal for 2019. He contends that Amedisys' valuation is now at an appropriate premium to its peer group.
11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/17
WBLR
11/21/17
INITIATION
WBLR
Outperform
Amedisys initiated with an Outperform at William Blair
William Blair started Amedisys with an Outperform rating.
11/09/17
CHLM
11/09/17
NO CHANGE
Target $68
CHLM
Buy
Amedisys price target raised to $68 from $55 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Amedisys to $68 from $55 following "solid" Q3 results and as Home Health is about to turn the corner. The analyst reiterates a Buy rating on the shares.
CI Cigna
$207.09

-0.78 (-0.38%)

01/05/18
LEER
01/05/18
NO CHANGE
LEER
Leerink views Department of Labor guidance as positive for MCOs
The Department of Labor's guidance yesterday on expanding access to Association health plans could be negative for both acute and behavioral health facilities due to healthcare exchange dis-enrollment into less rich benefit plans, Leerink analyst Ana Gupte tells investors in a research note. The news, however, is positive for large commercial group employer focused managed care organizations such as UnitedHealth (UNH), Anthem (ANTM), Aetna (AET) and Cigna (CI), with limited to no downside for Centene (CNC) and Molina Healthcare (MOH), given their focus on low income exchange members, the analyst adds. She believes WellCare (WCG) will not be impacted. Gupte expects the level of coverage per insured life to deteriorate with the Department of Labor's order as "skinnier and short term health plans that partly circumvent the ten mandated Essential Health Benefits from the Affordable Care Act further reduce utilization."
01/03/18
GSCO
01/03/18
INITIATION
Target $247
GSCO
Neutral
Cigna initiated with a Neutral at Goldman Sachs
Goldman analyst Stephen Tanal initiated Cigna with a Neutral and $247 price target due to valuation.
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
12/28/17
LEER
12/28/17
NO CHANGE
LEER
CMS Medicare Advantage Payment Notice positive for Humana, UnitedHealth, says Leerink
Leerink analyst Ana Gupte views the CMS 2019 Medicare Advantage Payment Notice with Methodological Changes on Risk Adjusters as a likely positive precursor to the actual rate change and a positive catalyst. The analyst believes the notice is most positive for Humana (HUM), UnitedHealth (UNH) and WellCare (WCG), but also positive for the sector as a whole including Aetna (AET), Cigna (CI), Anthem (ANTM), Centene (CNC) and Molina Healthcare (MOH). The notice offers a change in the risk adjustment methodology that is more industry friendly than the status quo and this combined with a 4% underlying cost trend expectation should offer a positive advance rate announcement in February and final in April. Gupte also expects that the Republican Administration will drive tax reform as part of an imperative to reaccelerate what is likely irreversible privatization of Medicare, after the slowdown as part of the budget cuts in the era of ObamaCare.
MYOK MyoKardia
$48.45

0.9 (1.89%)

12/12/17
JPMS
12/12/17
INITIATION
Target $54
JPMS
Overweight
MyoKardia initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started MyoKardia with an Overweight rating and $54 price target. The analyst views the company's novel precision medicine approach in cardiovascular diseases as underappreciated.
08/07/17
WELS
08/07/17
NO CHANGE
Target $48
WELS
Outperform
MyoKardia price target raised to $48 from $31 at Wells Fargo
Wells Fargo analyst Jim Brichenough raised MyoKardia's price target to $48 from $31 and reiterated his Outperform rating following review of top-line PIONEER results. The analyst said result were better than expected and bode well for Phase 3 success in the planned EXPLORER study.
08/07/17
COWN
08/07/17
NO CHANGE
Target $56
COWN
Outperform
MyoKardia price target raised to $56 from $28 at Cowen
09/19/17
FBCO
09/19/17
NO CHANGE
Target $55
FBCO
Outperform
MyoKardia price target raised to $55 from $45 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for MyoKardia to $55 from $45 following updated results for the PIONEER-HCM study for its mavacamten in obstructive hypertrophic cardiomyopathy, or HCM. Following conversations with an expert in the field, investors, and company management, the analyst maintains his 75% Probability of Success for mavacamten in obstructive HCM. Divan reiterates an Outperform rating on the shares.
PODD Insulet
$75.83

0.75 (1.00%)

01/08/18
01/08/18
UPGRADE
Target $80

Outperform
Insulet upgraded to Outperform on upcoming tailwinds at Raymond James
As previously reported, Raymond James upgraded Insulet (PODD) to Outperform from Market Perform and established an $80 price target. Analyst Jayson Bedford has increased confidence in estimates from several tailwinds that include a share gain opportunity in US insulin pumps following Johnson & Johnson's (JNJ) exit from the market in September, incremental Medicare reimbursement for OmniPod, potential growth as it enters new countries, and the expected launch of its new Bluetooth-enabled OmniPod and PDM, its first new product in five years.
01/08/18
RAJA
01/08/18
UPGRADE
RAJA
Outperform
Insulet upgraded to Outperform from Market Perform at Raymond James
01/08/18
LEER
01/08/18
NO CHANGE
LEER
Outperform
Meaningful upside likely for Insulet in 2019, says Leerink
Leerink analyst Danielle Antalffy notes that Insulet announced that CMS has granted coverage of its OmniPod. While the analyst says this coverage decision was well expected, she believes it positions the company for potential upside to his 2018 sales estimates and sees meaningful upside likely in 2019 and beyond. Antalffy reiterates an Outperform rating on the shares.
01/07/18
PIPR
01/07/18
NO CHANGE
Target $65
PIPR
Overweight
Piper Jaffray sees Medicare covering Omnipod as incremental positive for Insulet
Piper Jaffray analyst JP McKim notes that Senator Susan Collins tweeted that Medicare will start covering Insulet's Omnipod, which he sees as an incremental win for the company but not exactly what he had expected. Specifically, CMS views Omnipod as a Part D which is what Insulet wanted but CMS does not require their Part D sponsors to include Omnipod on their formularies, McKim notes. While the Medicare door is ajar for Omnipod, the analyst believes it is not fully opened just yet as Insulet will now have to get on each plan sponsors formulary, a task that will take further time and resources. He reiterates an Overweight rating and $65 price target on the shares.
AXON Axovant Sciences
$2.43

0.05 (2.10%)

01/09/18
JMPS
01/09/18
NO CHANGE
Target $11
JMPS
Outperform
JMP says Axovant data still support nelotanserin advancement
JMP Securities analyst Jason Butler acknowledges that the nelotanserin Phase 2 results reported by Axovant Sciences were not the best-case outcome, but he remains encouraged by the efficacy signals seen in this small, short-term trial and still thinks the results support clinical advancement. He maintains a 65% probability of approval for nelotanserin, but pushed out his launch expectation to 2022 from 2020. Butler cut his price target on Axovant to $11 from $19 but keeps an Outperform rating on the shares, which fell 57% yesterday to $2.31.
12/21/17
JEFF
12/21/17
DOWNGRADE
Target $6
JEFF
Hold
Axovant Sciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee downgraded Axovant Sciences to Hold and cut his price target for the shares to $6 from $12. The company needs "more interesting" in-licensed compounds to renew investor interest in 2018 and to demonstrate the new CEO can drive shareholder value, Yee tells investors in a research note. The analyst views the stock's risk/reward as balanced at current levels.
12/21/17
12/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PG&E (PCG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Shelby Tucker stating that the company's "unexpected" decision to suspend its dividend suggests greater risk than he had assumed regarding the regulatory treatment of the California wildfires in October. 2. ConocoPhillips (COP) downgraded to Outperform from Focus List at Scotia Howard Weil. 3. Axovant Sciences (AXON) downgraded to Hold from Buy at Jefferies with analyst Michael Yee saying the company needs "more interesting" in-licensed compounds to renew investor interest in 2018 and to demonstrate the new CEO can drive shareholder value. 4. Lazard (LAZ) downgraded to Neutral from Buy at Buckingham with analyst James Mitchell saying he sees little operating leverage from the tax rate cut and said weakening restructuring revenues will be a drag on growth. 5. SunTrust (STI) downgraded to Neutral from Outperform at Wedbush with analyst Peter Winter citing valuation with the shares up 19% year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/18
CHDN
01/10/18
UPGRADE
CHDN
Neutral
Axovant Sciences upgraded to Neutral from Sell at Chardan
Chardan analyst Gbola Amusa upgraded Axovant Sciences to Neutral from Sell citing share underperformance and lowered its price target to $2 from $2.50.
IPXL Impax
$17.35

0.05 (0.29%)

12/12/17
12/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL), Teva (TEVA) and Endo (ENDP) initiated with a Neutral at Gugenheim, while Impax (IPXL) was initiated with a Buy. 2. Stitch Fix (SFIX) initiated with an Outperform at William Blair, a Neutral at JPMorgan and Goldman Sachs, an Overweight at Piper Jaffray, an Equal Weight at Barclays and a Hold at Stifel. 3. Exxon Mobil (XOM) and ConocoPhillips (COP) initiated with a Neutral at Credit Suisse. The firm also started Range Resources (RRC) and Anadarko (APC) with an Outperform, and Laredo Petroleum (LPI), Energen (EGN), Southwestern Energy (SWN), Noble Energy (NBL), Murphy Oil (MUR), Cabot Oil & Gas (COG) and Newfield Exploration (NFX) with a Neutral rating. 4. Restaurant Brands (QSR) initiated with an Outperform at Evercore ISI. 5. Waste Connections (WCN) initiated with an Outperform, named a top pick at BMO Capital. This list is just a portion of The Fly's full analyst coverage. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
GUGG
12/12/17
INITIATION
Target $18
GUGG
Buy
Impax initiated with a Buy at Guggenheim
Guggenheim analyst Rohit Vanjani initiated Impax with a Neutral and $18 price target. Vanjani said shares trade at a premium to the group and recent misses with the generic Renvela and Concerta highlights the need for more ANDAs.
10/18/17
ADAM
10/18/17
NO CHANGE
Target $19
ADAM
Hold
Impax deal positive but value creation may take time, says Canaccord
Canaccord analyst Dewey Steadman said he is positive on Impax's deal to combine with Amneal, but he expects the value creation to gradually come over time as the new company delivers on growth expectations well above its generic peers given its newly-created critical mass. Steadman maintained his Hold rating and $19 price target on Impax shares.
01/02/18
LEER
01/02/18
INITIATION
Target $22
LEER
Outperform
Impax initiated with an Outperform at Leerink
Leerink analyst Ami Fadia initiated Impax with an Outperform and $22 price target given its long-term sector-leading sales growth profiles, margin expansion. and flexible capital deployment. Fadia's above consensus estimates reflect the NewCo's strong pipeline and synergies and expects improved visibility into earnings growth to drive further shares momentum.
FMI Foundation Medicine
$69.65

1.5 (2.20%)

03/07/17
JANY
03/07/17
UPGRADE
JANY
Neutral
Foundation Medicine upgraded to Neutral from Sell at Janney Capital
Janney Capital analyst Paul Knight upgraded Foundation Medicine (FMI) to Neutral from Sell, citing "easy" earnings comparisons in Q1 and low expectations. In his upgrade note, Knight added that if Foundation's recent rebound is due to a change in sector perception, then he views Veracyte (VCYT), CaredDx (CDNA), and Oncocyte (OCX) as having "more catalysts, more revenue visibility, and better value" and sees all three as undervaled.
04/03/17
WBLR
04/03/17
NO CHANGE
WBLR
Outperform
William Blair sees more upside for Foundation Medicine despite recent rally
After revisiting her thesis with the stock up 82% year-to-date, William Blair analyst Amanda Murphy continues to see potential for upside in Foundation Medicine shares. The analyst is unable to pinpoint a specific catalyst for the move higher, but notes short covering likely played a role while reimbursement fundamentals appear to have shifted in the company's favor over the past few weeks. The analyst sees potential for 20%-30% in compound annual revenue growth over the next five years for Foundation and keeps an Outperform rating on the name.
05/15/17
BTIG
05/15/17
UPGRADE
Target $39
BTIG
Buy
Foundation Medicine upgraded to Buy from Neutral at BTIG
BTIG analyst Karen Koski upgraded Foundation Medicine to Buy from Neutral and established a $39 price target. The analyst expects Foundation to continue to benefit from educational efforts in the community setting, progress in CMS reimbursement, expanded product portfolio, and focus on improving clinical actionability of CGP.
THC Tenet
$14.77

-0.34 (-2.25%)

12/20/17
LEER
12/20/17
NO CHANGE
Target $27
LEER
Outperform
Value may be unlocked through Tenet sale of Conifer, says Leerink
Leerink analyst Ana Gupte raised her price target for Tenet to $27 from $25 on increased confidence that value may be unlocked through the active sale of Conifer. The analyst believes Conifer sales proceeds could be used for further debt reduction or growth opportunities in the ambulatory segment. He reiterates an Outperform rating on the shares.
12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
HCA Healthcare, Tenet downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Zack Sopcak downgraded HCA Healthcare (HCA) and Tenet (THC), both to Underweight from Equal Weight, contending that the recently announced deals made by Aetna (AET) for CVS Health (CVS) and UnitedHealthcare (UNH) for DaVita Medical Group highlight the ways payers are becoming increasingly vertically integrated and focusing on reducing medical costs. After analyzing CVS Health's overlap with hospitals and hospitals' exposure to CVS and UnitedHealth (UNH) clinics in states with above average Medicare Advantage share, Sopcak found HCA and Tenet to be most exposed, he tells investors. Noting that he sees the valuations of both as full, he raised his price target on HCA to $84 from $79 and increased his target on Tenet to $15 from $14.
01/03/18
GSCO
01/03/18
INITIATION
Target $15
GSCO
Neutral
Tenet initiated with a Neutral at Goldman Sachs
Goldman analyst Stephen Tanal initiated Tenet with a Neutral and $15 price target due to unattractive payor mix, difficult local positioning, and competitive threats.
12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
Tenet downgraded to Underweight from Equal Weight at Morgan Stanley
VAR Varian Medical
$111.68

-1.25 (-1.11%)

01/03/18
EVER
01/03/18
INITIATION
Target $100
EVER
Underperform
Varian Medical initiated with an Underperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Varian Medical with an Underperform rating and $100 price target. He believes the stock "may be getting ahead of itself," as he believes its recent rally is at odds with the company's FY18 guidance for revenue growth of 2%-4%.
09/07/17
BTIG
09/07/17
DOWNGRADE
BTIG
Neutral
Varian Medical downgraded on valuation, macro concerns at BTIG
As noted earlier, BTIG downgraded Varian to Neutral from Buy. Analyst Sean LAvin said he downgraded the stock "mainly on valuation." However, he also believes that the company's results could be hurt by "instability in Korea and multiple hurricanes."
05/16/17
GSCO
05/16/17
INITIATION
Target $92
GSCO
Neutral
Varian Medical initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Isaac Ro started Varian Medical Systems with a Neutral rating and $92 price target. The company's new product cycle is unlikely to drive accelerated earnings growth, the analyst contends.
09/07/17
09/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. trivago (TRVG) downgraded to Neutral from Buy at BofA/Merrill with analyst Nat Schindler citing a surprise lowering of its 2017 revenue growth target to 40% from 50% and reduced adjusted EBITDA to down year-over-year. 2. Carrizo Oil & Gas (CRZO) downgraded to Neutral from Buy at Mizuho with analyst Timothy Rezvan saying Carrizo faces too many near-term headwinds and doesn't see Net Asset Value upside driving near-term stock outperformance. 3. Varian Medical (VAR) downgraded on valuation, macro concerns at BTIG with analyst Sean LAvin saying he downgraded the stock "mainly on valuation." However, he also believes that the company's results could be hurt by "instability in Korea and multiple hurricanes." 4. Zymeworks (ZYME) assumed with an Underweight from Overweight at Barclays with analyst Gena Wang saying she has low expectations for the company's lead asset HER2 dispecific antibody ZW25 in HER and high and medium expressed breast cancer. 5. Sealed Air (SEE) downgraded to Neutral from Buy at Citi with analyst Anthony Pettinari saying the company's annual guidance is at risk due to resin headwinds post Hurricane Harvey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$197.84

2.11 (1.08%)

05:00
01/23/18
01/23
05:00
01/23/18
05:00
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ATUS

Altice USA

$21.90

0.6 (2.82%)

, ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:58
01/23/18
01/23
04:58
01/23/18
04:58
Upgrade
Altice USA, Altice NV rating change  »

Altice USA upgraded to…

ATUS

Altice USA

$21.90

0.6 (2.82%)

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Upgrade
Altice NV rating change  »

Altice NV upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

RHT

Red Hat

$128.01

2.07 (1.64%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Red Hat participates in a conference call with Bernstein »

U.S. SMID-Cap Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

CAMP

CalAmp

$23.13

0.02 (0.09%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
CalAmp has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AYR

Aircastle

$24.23

-0.03 (-0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

CRNCY

Cairn Energy

$6.15

0.11 (1.82%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Cairn Energy management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SRE

Sempra Energy

$105.05

-0.94 (-0.89%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Sempra Energy management to meet with Wolfe Research »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TRN

Trinity Industries

$36.51

-0.15 (-0.41%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Trinity Industries management to meet with Wedbush »

Meeting with CFO Perry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SBOW

SilverBow Resources

$31.45

-0.79 (-2.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
SilverBow Resources management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

BNED

Barnes & Noble Education

$7.71

0.01 (0.13%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRG

Bluerock Residential

$9.22

0.03 (0.33%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

FCPT

Four Corners Property Trust

$24.13

0.45 (1.90%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Four Corners Property Trust management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SIG

Signet Jewelers

$55.87

0.8 (1.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Signet Jewelers management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

UNF

UniFirst

$171.15

0.2 (0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UniFirst management to meet with Northcoast »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PRQR

ProQR Therapeutics

$3.03

0.025 (0.83%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 19

    Feb

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

, CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

NBLX

Noble Midstream

$56.22

1.12 (2.03%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

WGP

Western Gas Equity

$41.91

1.49 (3.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

, CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UBS to hold a tour »

Houston Winter MLP &…

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SEP

Spectra Energy Partners

$43.40

0.81 (1.90%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 09

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Abeona Therapeutics management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

STML

Stemline

$14.25

0.7 (5.17%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Stemline participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

Week of 1/19 Redbook to…

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

Chicago Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.